NO.1 PHARMACY(SH:600833)2020-10-29 16:00Financial Performance - Operating revenue for the first nine months rose by 29.95% to CNY 1,194,693,121.84 year-on-year[7] - Net profit attributable to shareholders increased by 51.06% to CNY 57,677,849.44 compared to the same period last year[7] - Basic earnings per share increased by 50.99% to CNY 0.2585[7] - Total profit for the period was ¥75,982,998.71, a 50.96% increase from ¥50,333,179.43, attributed to higher sales of epidemic prevention products and compensation received for land acquisition[15] - Net profit for Q3 2020 was $24.41 million, compared to $7.99 million in Q3 2019, representing a 205.01% increase[26] - The company reported a net profit of $57.68 million for the first three quarters of 2020, up from $38.18 million in the same period of 2019, reflecting a growth of 51.24%[26] Asset and Liability Changes - Total assets increased by 14.82% to CNY 1,396,797,003.64 compared to the end of the previous year[7] - The company reported a significant increase in short-term loans, totaling CNY 180,000,000.00, reflecting new bank loans obtained during the reporting period[14] - Total current liabilities increased to ¥581,945,030.23 from ¥422,230,117.31, representing a 37.8% increase year-over-year[20] - Total liabilities increased to ¥653,438,909.48 from ¥309,005,285.76, reflecting a 111.5% rise year-over-year[22] - The company’s total non-current liabilities decreased to ¥48,388,924.86 from ¥53,465,510.98, a decline of 9.9%[22] Cash Flow Analysis - Cash flow from operating activities decreased by 34.37% to CNY 44,594,762.79 compared to the same period last year[7] - The net cash flow from operating activities for the first three quarters of 2020 was ¥85,484,631.12, an increase of 82% compared to ¥46,967,182.02 in the same period of 2019[30] - The net cash flow from financing activities was CNY 161.19 million in the first three quarters of 2020, compared to a negative cash flow of CNY 14.50 million in the same period of 2019[28] - Cash inflow from financing activities amounted to ¥180,000,000.00, with a net cash flow of ¥161,188,803.42 after accounting for cash outflows[30] Shareholder Information - The number of shareholders reached 26,354, with the largest shareholder, Bailian Group Co., Ltd., holding 44.95% of the shares[10] - Shareholders' equity totaled ¥698,244,207.23, slightly up from ¥689,082,071.38, showing a 1.7% increase[22] Operational Insights - The company has indicated that the current business growth has returned to normal levels following the peak demand for epidemic prevention materials, but future operations remain uncertain due to ongoing global pandemic risks[15] - The company reported a significant increase in other income, which rose by 121.19% to ¥19,386,511.08, compared to ¥8,764,758.88 in the previous year, due to compensation received for land acquisition[15] Inventory and Expenses - The inventory level stood at ¥227,119,943.73, slightly up from ¥220,729,381.22 at the end of 2019, indicating stable stock levels amid increased sales[19] - Operating costs rose to ¥980,425,397.82, reflecting a 33.21% increase from ¥735,978,784.22, also driven by the growth in sales of epidemic prevention materials[15] - Sales expenses decreased to CNY 6.66 million in Q3 2020, down 57.0% from CNY 15.54 million in Q3 2019[27] - The company incurred management expenses of CNY 18.35 million in Q3 2020, a significant increase from CNY 5.61 million in Q3 2019[27]